کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2137654 | 1087854 | 2011 | 5 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Doxorubicin-containing chemotherapy is the standard regimen for elderly patients with aggressive lymphoma. However, many of them cannot receive it due to severe associated comorbidities. Toxicity and efficacy of intermediate doses of nonpegylated liposomal doxorubicin (NPLD) in modified-CHOP regimen ± Rituximab were prospectively analyzed in 35 frail elderly patients (median age: 76 years) with previously untreated aggressive lymphoma with one or more severe comorbidities. NPLD at intermediate doses (30 mg/m2) is effective and well tolerated in these patients. In addition, NT-proBNP levels >900 ng/ml at diagnosis have demonstrated to be a good predictor for OS and PFS in this cohort of patients.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 35, Issue 3, March 2011, Pages 358–362
Journal: Leukemia Research - Volume 35, Issue 3, March 2011, Pages 358–362
نویسندگان
Eva Gimeno, Blanca Sánchez-González, Alberto Álvarez-Larrán, Carmen Pedro, Eugenia Abella, Josep Comín, Silvia Saumell, Francesc García-Pallarols, Miquel Gómez, Carles Besses, Antonio Salar,